These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 10732888)
1. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schleef M; Seyfarth M; Dirschinger J; Schömig A J Am Coll Cardiol; 2000 Mar; 35(4):915-21. PubMed ID: 10732888 [TBL] [Abstract][Full Text] [Related]
2. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R; JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414 [TBL] [Abstract][Full Text] [Related]
3. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
4. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230 [TBL] [Abstract][Full Text] [Related]
5. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW; Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213 [TBL] [Abstract][Full Text] [Related]
8. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
9. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748 [TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542 [TBL] [Abstract][Full Text] [Related]
12. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Neumann FJ; Blasini R; Schmitt C; Alt E; Dirschinger J; Gawaz M; Kastrati A; Schömig A Circulation; 1998 Dec; 98(24):2695-701. PubMed ID: 9851955 [TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A; Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766 [TBL] [Abstract][Full Text] [Related]
14. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Costantini CO; Stone GW; Mehran R; Aymong E; Grines CL; Cox DA; Stuckey T; Turco M; Gersh BJ; Tcheng JE; Garcia E; Griffin JJ; Guagliumi G; Leon MB; Lansky AJ J Am Coll Cardiol; 2004 Jul; 44(2):305-12. PubMed ID: 15261923 [TBL] [Abstract][Full Text] [Related]